NasdaqCM:CPRXBiotechs
How Investors May Respond To Catalyst Pharmaceuticals (CPRX) Delaying FIRDAPSE Generics Through Lupin Patent Settlement
In August 2025, Catalyst Pharmaceuticals announced a settlement with Lupin Ltd. that resolves patent litigation over a generic version of FIRDAPSE, delaying potential U.S. market entry for Lupin’s product until at least February 2035 pending FDA approval.
This agreement helps secure FIRDAPSE’s U.S. market exclusivity for an additional decade, while patent challenges from other generic companies remain ongoing.
We'll now explore how securing FIRDAPSE's exclusivity through the Lupin settlement...